Elicera Therapeutics: On the right path - Redeye
Bildkälla: Stockfoto

Elicera Therapeutics: On the right path - Redeye

Redeye revisits some assumptions related to financing and likelihood of approval following the progress with the CARMA study and the recent share price development, leading to a raised valuation.

Redeye revisits some assumptions related to financing and likelihood of approval following the progress with the CARMA study and the recent share price development, leading to a raised valuation.
Börsvärldens nyhetsbrev
ANNONSER